Speaking Monday night to investors on a conference call, CytoDyn CEO Nader Pourhassan said the company had requested a “conditional” emergency use authorization from the Food and Drug Administration for an experimental Covid-19 antibody treatment, despite its failure in a late-stage clinical trial.
But a “conditional” EUA — as described by CytoDyn’s CEO — does not exist.
“If you look at the law there is no such thing. You can certainly say that,” an FDA official told STAT on Wednesday, in response to the claims made by CytoDyn. The official asked not to be identified because of rules barring the agency from discussing regulatory matters involving unapproved drugs.
About the Author Reprints
I see you censored my first comment. Afraid of the truth, Adam? Afraid that people will finally see that you’re a paid shill for a known short seller of CytoDyn, Joeseph Seigel of Buyerstrike.
Another “article” full of lies and distortions. Direct from the FDA’s website: “FDA may establish conditions on an EUA necessary or appropriate to protect the public health.” (Link below) That sentence destroys the entire premise of your story and anyone reading it should not believe anything else that you write. You’re not even trying to be objective and it’s completely obvious here.
Purposefully writing lies and distortions about CytoDyn is worsening the world’s COVID misery and you should be ashamed. You are an evil human being.
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/emergency-use-authorization-medical-products-and-related-authorities#conditions